99 results about "Intestinal colonization" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to a plant lactobacillus B534 strain and application thereof in preparation of functional products beneficial to sleep improvement and emotion regulation. The lactobacillus plantarum B534 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the lactobacillus plantarum B534 is CGMCC No.33031. The lactobacillus plantarum B534 is named as lactobacillus plantarum B534. The plant lactobacillus B534 provided by the invention is a natural strain and has food safety; the lactobacillus plantarum B534 has relatively strong acetylcholin esterase inhibition activity, and also has relatively strong capability of synthesizing and secreting GABA (gamma-aminobutyric acid), 3-HB (3-hydroxybutyric acid) and 5-HT (5-hydroxytryptamine); meanwhile, the plant lactobacillus B534 has relatively strong acid resistance and cholate resistance and also has relatively strong tolerance to simulated gastrointestinal fluid, so that the plant lactobacillus B534 has relatively good intestinal colonization ability and has important application value in the fields of products beneficial to sleep improvement, emotion regulation products and the like.

A breast milk-derived Limosilactobacillus fermentum MSJK0025 capable of improving the intestinal flora condition and the use thereof. The breast milk-derived Limosilactobacillus fermentum MSJK0025 is deposited in the China General Microbiological Culture Collection Center with a deposit number of CGMCC No. 26426. The breast milk-derived Limosilactobacillus fermentum is a new strain isolated from breast milk of healthy puerperae, and is referred to as Limosilactobacillus fermentum MSJK0025. The strain has a good antibiotic sensitivity and stable inheritance of traits, has a good tolerance to acid, bile salts and artificial gastric / intestinal fluid, and has a fast growth rate and good safety. Furthermore, the strain has a strong intestinal colonization capability and can effectively inhibit intestinal pathogenic bacteria such as Escherichia coli, Staphylococcus aureus, Salmonella typhimurium and Candida albicans, but has no inhibitory effects on intestinal probiotics such as Lactobacillus and Bifidobacterium.

The invention relates to the field of microorganisms, and discloses an aspergillus cristatus strain and application thereof. The preservation number of the aspergillus cristatus provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.41727. The aspergillus cristatus provided by the invention can produce chymosin at high yield, has excellent curding activity and relatively low proteolytic activity, and can reduce the bitter taste of dairy products and improve the yield; the aspergillus cristatus provided by the invention not only can shorten the fermentation time of the dairy product, improve the cream flavor of the dairy product, reduce the peculiar smell of the dairy product, balance the sourness and sweetness of the dairy product and improve the cinnamon flavor, but also has intestinal colonization ability, and has the potential of improving the flavor level of the dairy product and becoming intestinal probiotics.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium longum subsp. Longum as well as a composition, a pharmaceutical composition, a culture, a food product or a dietary supplement containing the bifidobacterium longum subsp. Longum and application of the bifidobacterium longum subsp. Longum. The bifidobacterium longum is preserved in the Guangdong Microbial Culture Collection Center on January 21, 2025, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No.65836. The bifidobacterium longum subsp. Longum has relatively strong gastric acid and cholate tolerance and intestinal colonization capability; the bifidobacterium longum subsp. Longum can effectively utilize bifidobacterium bifidum to release monosaccharide or disaccharide outside cells for efficient proliferation, and the composition containing the bifidobacterium longum subsp. Longum, the bifidobacterium bifidum and breast milk oligosaccharide can release a large amount of short-chain fatty acid, so that the effects of maintaining the physiological function of an organism and improving the health of the organism are achieved.

The invention provides a halite-containing probiotic preparation for improving gastrointestinal environment and a preparation method, the halite-containing probiotic preparation comprises the following components in parts by weight: 60-70 parts of a probiotic composition, the probiotic composition comprises lactobacillus casei Zhang, animal bifidobacterium subsp. Lactis V9, lactobacillus plantarum P-01, animal bifidobacterium subsp. Lactis B-01 and casei paracasei LC-11, the weight ratio is 3: 2: 2: 1: 1. 1.2 to 3.5 parts of nanoscale refined halite; 10 to 15 parts of a microcapsule embedding material; 0.6 to 1.2 parts of an antioxidant system; 15 to 30 parts of auxiliary materials; the probiotic preparation disclosed by the invention has the characteristics of obvious strain combination advantage, nano-scale halite protection and synergism, accurate release of a multi-layer microcapsule structure, synergistic effect of an antioxidant system and the like, the survival rate of probiotics, gastrointestinal tract tolerance and intestinal colonization capacity are remarkably improved, and a new technical scheme is provided for improving gastrointestinal health.

The invention discloses a functional probiotic composition and application thereof, and relates to the technical field of microbial engineering. Bifidobacterium longum, lactobacillus acidophilus and enterococcus faecalis are combined to serve as a microbial agent, the microbial agent and active substances of the tea leaves form a composition, then the composition is combined with prebiotics, it is ensured that viable bacteria directly reach the intestinal tract through a microencapsulation technology, and the effect of improving the immune function is achieved; tea polyphenol in the active substances of the tea leaves can serve as a carbon source of prebiotics to stimulate proliferation of the bifidobacterium longum and the lactobacillus acidophilus, so that the acid resistance and intestinal colonization capacity of the microbial inoculum are enhanced, and meanwhile, theanine in the active substances of the tea leaves, the bifidobacterium longum and the lactobacillus acidophilus synergistically promote secretion of gamma-aminobutyric acid, so that the effect of improving the intestinal colonization is achieved. And the tea polyphenol can inhibit the large intestine rod from adhering to the intestinal mucosa, and the probiotic agent secretes antibacterial peptide, so that the integrity of the intestinal barrier is maintained together.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention provides a feline animal bifidobacterium, a metagen, a pharmaceutical composition and application, the feline animal bifidobacterium is named as animal bifidobacterium GYJC-001, the strain is preserved in the China Center for Type Culture Collection on July 22, 2024, and the preservation number is CCTCC NO: M 20241621. The invention further provides a preparation method of the feline animal bifidobacterium, the metagen, the pharmaceutical composition and the application of the feline animal bifidobacterium, the metagen, the pharmaceutical composition and the application of the feline animal bifidobacterium, the metagen, the pharmaceutical composition and the application of the feline animal bifidobacterium. The bifidobacterium animalis GYJC-001 disclosed by the invention has the advantages that the acid resistance and cholate resistance are high, the intestinal colonization ability is strong, the probiotic effect is better, the toxic and side effects are avoided, and a certain theoretical basis is provided for the development of the bifidobacterium animalis GYJC-001.

The present invention relates to the field of microbial technology, and specifically discloses a thermotolerant Propionibacterium freudenreichii subsp. shermanii strain PF37 and its application in intestinal colonization and symbiosis. The thermotolerant Propionibacterium freudenreichii subsp. shermanii strain PF37 was deposited with the China General Microbiological Culture Collection Center on March 21, 2025, and its deposit number is CGMCC No. 46389. This strain still has the ability of proliferation activity, fermenting and producing short-chain fatty acids, and promoting the colonization and proliferation of Bifidobacterium in the intestine at 34-37°C.

The invention belongs to the technical field of probiotics, and particularly relates to probiotics for improving intestinal health and application thereof. Wherein the probiotics for improving the intestinal health are a Lactobacillus plantarum LV1000 strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.30865, and the strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on June 5, 2024; through unique activation culture, streak separation and bacterial colony identification steps, high activity and high purity of the strain are ensured; based on the application of the strain, two product forms of probiotic microcapsules and probiotic compositions are developed, the probiotic microcapsules adopt sodium alginate, calcium lactate and other raw materials, the intestinal colonization ability of the strain is effectively improved, and the synergistic interaction of oxidation resistance and immunoregulation is achieved by combining rosa roxburghii tratt freeze-dried powder; and the probiotic composition can comprehensively regulate the balance of intestinal flora and improve the digestive function and intestinal motility.

The invention provides a bacillus subtilis strain and application thereof, the bacillus subtilis strain is named as bacillus subtilis Ya3.1, is preserved in China General Microbiological Culture Collection Center on July 7, 2025, and has a preservation number of CGMCC (China General Microbiological Culture Collection Center) No.35019; the bacillus subtilis Ya3.1 is separated from intestinal tracts of healthy hybrid sturgeons, and can be used as a probiotic additive for aquaculture, especially for sturgeon culture. The bacillus subtilis Ya3.1 provided by the invention has high safety, strong stress resistance and efficient intestinal colonization ability, and can significantly improve the activity of sturgeon intestinal digestive enzymes, improve the growth performance of sturgeons, enhance the non-specific immunity of sturgeons, improve the intestinal flora structure and significantly improve the ability to resist aeromonas bacterial infection; and a special probiotic resource can be provided for sturgeon culture.

The invention discloses a composition containing probiotics and fusion polypeptide and application of the composition in treatment of intestinal inflammatory diseases. The composition is prepared from lactobacillus plantarum (Lactobacillus plantarum CCFM8661) and a functional fusion polypeptide, wherein the amino acid sequence of the fusion polypeptide is as shown in SEQ ID NO. 1. The invention also discloses a preparation method of the composition. The fusion polypeptide can be used for directly inhibiting the growth of pathogenic bacteria and neutralizing toxins by enhancing the intestinal colonization capability of probiotics, so that the triple synergistic effect of bacteriostasis, repair and immunoregulation is realized. Experiments show that the composition significantly reduces the disease activity index in a DSS-induced mouse colitis model, recovers the colon length, and inhibits serum inflammatory factors IL-6 and TNF-alpha. In addition, the survival rate of the freeze-dried microcapsule preparation in simulated gastric juice is gt; the colon targeted release characteristic is realized. The invention provides an efficient and stable new treatment strategy for intestinal inflammatory diseases.

The present invention discloses a CBP lysine children growth milk powder and a preparation method thereof, and belongs to the technical field of milk powder, the CBP lysine children growth milk powder comprises the following components by mass: a wet process part: 575 parts of whole milk powder, 175 parts of dried skim milk, 175 parts of isomaltooligosacharide (type 50) powder, 30 parts of polydextrose, 28 parts of edible plant blend oil, 4 parts of milk mineral salt, and 13.7 parts of a compound children modified milk powder three-nutrition enhancer; cBP lysine is cooperated with bifidobacterium and seven traditional Chinese medicine extracts, DHA and ARA are accurately proportioned, the calcium absorption efficiency and the intestinal colonization capacity of probiotics are remarkably improved, a three-step mixing method is combined with a two-way shearing low-temperature technology, rapid and uniform mixing is achieved, the activity of the probiotics and the stability of DHA are reserved to the maximum extent, high uniformity of products is ensured, and the product quality is improved. The low-moisture wet-process base powder inhibits moisture absorption of traditional Chinese medicine components, nitrogen protection blocks oxidation in the whole process, the shelf life is prolonged, and the reconstituability is improved.

According to the probiotic gel microspheres disclosed by the invention, probiotics are wrapped by the gel microspheres, so that the probiotics are protected from being absorbed or the influence of gastric acid and intestinal digestive juice is reduced, and the release of the probiotics in intestinal tracts is promoted. When the probiotics adopt functional coatings, after the probiotics gel microspheres reach the intestinal tract and release the probiotics, the coating layers on the surfaces of the probiotics can promote the probiotics to adhere to the intestinal mucosa, and the problem that traditional probiotics are difficult to colonize in the intestinal tract is solved. The probiotic gel microspheres disclosed by the invention have an obvious radiation injury protection effect after being orally taken, and can be used for relieving whole-body radiation injury or local radiation injury (such as radioactive intestinal injury) caused by whole-body radiation or local radiation (such as abdominal radiotherapy).

According to the application disclosed by the invention, the new lactobacillus rhamnosus LR159 is found for the first time, and the strain can be used for effectively treating the inflammatory bowel disease by inhibiting the inflammation level, recovering the barrier function of intestinal mucosa and regulating and improving the intestinal microenvironment. Compared with known lactobacillus rhamnosus, the LR159 strain provided by the invention has better intestinal colonization ability, and can realize more lasting anti-inflammatory and mucous membrane repair effects by breaking through the limitation of pathological microenvironment of the inflammatory bowel disease, thereby enhancing the treatment effect of the inflammatory bowel disease. In conclusion, the lactobacillus rhamnosus LR159 has a great application prospect in preventing and treating the inflammatory bowel disease.

The invention belongs to the technical field of biology, and particularly discloses a pH response type probiotic-liposome hybrid system, a preparation method and application thereof, and the pH response type probiotic-liposome hybrid system comprises engineered escherichia coli Nissle 1917, pinocembrin-loaded biotinylated liposome and an enteric polymer; wherein the engineered escherichia coli Nissle 1917 is in non-covalent binding with the biotinylated liposome loaded with the pinocembrin through surface display streptavidin, so that EcNPIN is formed, and the EcNPIN is coated with an enteric polymer, so that the pH response type probiotic-liposome hybrid system is formed. The pH response type probiotic-liposome hybrid system EcNPIN-L provided by the invention can resist the acidic environment of the stomach, completes pH response release and colonization in the intestinal tract, solves the problems of lack of intestinal tract localization of drugs and low probiotic treatment efficiency, improves the local intestinal tract concentration of pinocembrin, and promotes intestinal tract colonization of probiotics.

The invention relates to the technical field of probiotic preparations, in particular to a process for preparing intestinal conditioning prebiotics from clostridium butyricum and radix astragali seu hedysari, which comprises the following steps: (1) multi-stage synergistic activation of clostridium butyricum; (2) carrying out composite enzymolysis on the astragalus extract; (3) symbiotic fermentation; (4) performing multi-layer embedding; the prepared prebiotics have a multi-dimensional intestine regulating mechanism, the bacteriostasis and mucous membrane repairing functions of the clostridium butyricum cooperate with the prebiotics effect and antioxidant activity of the astragalus polysaccharide to form a multi-protection system, and the intestinal flora imbalance is more effectively improved compared with single probiotics or prebiotics. The multi-layer embedding technology solves the problems of gastric acid inactivation and difficulty in intestinal colonization of probiotics, and spore induction of three-stage fermentation is matched, so that the viable count maintenance rate of the product is kept at a relatively high level after the product is stored for 6 months at normal temperature, and the shelf life is remarkably prolonged.

The invention provides a bifidobacterium longum subsp. Longum aFMT-102 strain, which is classified and named as Bifidobacterium longum subsp. Longum, is preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 65180. The invention also provides a preparation method of the bifidobacterium longum subsp. Longum aFMT-102 strain. The invention further provides a microbial preparation containing the aFMT-102 strain and application of the aFMT-102 strain and the microbial preparation in preparation of products for relieving intestinal tracts and relieving stress. Meanwhile, the invention also provides a product containing the strain aFMT-102 or a corresponding microbial preparation. The strain aFMT-102 is separated from excrement of healthy adults, has good acid resistance and bile salt resistance and relatively strong intestinal colonization ability, and has a remarkable effect in the aspects of relieving intestinal tracts and relieving pressure.

The invention discloses application of bifidobacterium longum subsp. Longum i772 in a product for promoting bone health, and belongs to the field of microbial engineering. The effective components of the product for promoting bone health comprise live bifidobacterium longum subsp. Longum i772 and / or inactivated bifidobacterium longum subsp. Longum i772. The product provided by the invention can effectively promote bone health no matter whether the product contains viable bacteria or inactivated bacteria, and experimental data shows that the probiotic agent containing the bifidobacterium longum subsp. Longum i772 can significantly improve the bone density, bone volume fraction and bone trabecula thickness in a female rat osteoporosis model, and has a good application prospect. The bone trabecula spacing in the female rat osteoporosis model is reduced; meanwhile, the strain has an intestinal colonization effect and can continuously play a role in promoting bone health in the intestinal tract, and the trouble of daily medication can be reduced. The food provided by the invention is suitable for promoting bone health and preventing and / or improving osteoporosis.

The invention discloses klebsiella pneumoniae and application thereof in production of indole-3-carboxylic acid (I3CA), and belongs to the fields of microbial technology, biological catalysis and fermentation engineering. The preservation number of the klebsiella pneumoniae is CCTCC NO: M 20252762, the classification name of the klebsiella pneumoniae is Klebsiella pneumoniae I3CA-02, the strain can efficiently convert tryptophan into I3CA in a time-dependent mode through a one-step method, high sensitivity to various clinically common antibiotics is kept, and the klebsiella pneumoniae has good intestinal colonization ability and safety, and can be used for preparing I3CA. The method has the potential of being directly applied to oral micro-ecological preparations and industrial production. The technical bottlenecks that the existing I3CA biosynthesis efficiency is low and the safety of recombinant bacteria is limited are broken through, the microorganism sources of indole derivatives are widened, and a foundation is laid for green manufacturing of high-purity I3CA and development of intestinal-brain-immune axis related functional products.

The invention relates to a microbial single-cell gelation encapsulation method based on aloe gel and application, the method realizes single-cell gelation encapsulation through electrostatic interaction of sterile aloe gel and intestinal anaerobic bacteria (such as Agathobacter rectasis), and the method comprises the specific steps of aloe gel preparation, bacterial suspension culture and oscillation mixing to form a stable structure. The preparation method has the advantages that the acid resistance and biocompatibility of the natural aloe gel are utilized to replace a traditional synthetic material, so that the gastrointestinal tolerance of thalli is improved; meanwhile, the synergistic effect of aloe active ingredients (such as aloe-emodin) and intestinal bacterial metabolites (butyric acid) is combined, so that the anti-inflammatory and intestinal steady-state regulation and control effects are enhanced. Experiments show that the survival rate of the encapsulated bacteria in simulated gastric juice within 4 hours is larger than or equal to 90%, the intestinal colonization rate is effectively increased compared with naked bacteria, the inflammatory factor level of a colitis model mouse can be remarkably reduced, and a safe and efficient new strategy is provided for micro-ecological treatment of inflammatory bowel diseases.

The invention discloses a probiotic strain Bifidobacterium animalis subsp. Lactiss S8 of a high-yield biological membrane, the preservation number is GDMCC NO.66518, the characteristics of the stable high-yield biological membrane are obtained through directional screening and adaptive evolution, and the yield of the biological membrane is three times higher than that of a positive control. The extracellular polymeric substance (EPS) of the strain can significantly enhance the tolerance of the strain to severe environments such as gastric acid, cholate and the like, and improve the intestinal colonization ability. Experiments prove that the strain remarkably reduces two liver function indexes, namely ALT and AST, in an animal model, and shows that the strain has a certain effect of improving liver injury.

The invention discloses a saccharomyces boulardii colon delivery system which comprises the following steps: the survival rate in gastric juice is enhanced, and the residence time in the colon is increased, so that the treatment effect of the saccharomyces boulardii is enhanced. Saccharomyces boulardii is taken as a research object, in order to improve the bioavailability of the Saccharomyces boulardii in gastrointestinal tracts and prolong the adhesion time of bacteria in intestinal tracts, a layer-by-layer electrostatic self-assembly method is adopted, PDAD (poly dimethyl diallyl ammonium chloride), PSS (sodium polystyrene sulfonate), CS (chitosan) and SA (sodium alginate) are taken as biological membranes to coat the Saccharomyces boulardii, and the coated Saccharomyces boulardii is prepared. Then a series of characterization is carried out, and the effect of the delivery system is verified through in-vitro artificial gastric juice tolerance tests and mouse intestinal colonization.

The invention discloses application of lactobacillus plantarum LP-Y01 and a fungicide thereof in preparation of a medicine for preventing and / or treating carbapenem-resistant drug-resistant bacterium infection. The invention verifies that the lactobacillus plantarum can generate a direct inhibition effect on carbapenem-resistant klebsiella pneumonia in vitro and has certain effective activity on colonization of the carbapenem-resistant klebsiella pneumonia in vivo through flora regulation and control. Probiotic pretreatment shows remarkable clinical potential by regulating and controlling a flora structure, provides a precise strategy for prevention and control of drug-resistant bacteria, and has a relatively good application prospect.

The invention relates to the technical field of nano engineering and probiotics, in particular to a bacteriostatic composition and a fungicide, a veterinary drug and a feed containing the bacteriostatic composition. The invention provides a bacteriostatic composition prepared by simultaneously mixing nano iron sulfide and lactobacillus, which can protect the intestinal colonization ability of lactobacillus and other beneficial bacteria, so that the nano iron sulfide promotes bacterial ferroptosis of pathogenic bacteria in the intestinal tract. The nano iron sulfide and the lactobacillus synergistically inhibit the growth of pathogenic bacteria such as escherichia coli, salmonella typhimurium and staphylococcus aureus in vitro and in intestinal tracts, have no adverse effect on beneficial bacteria and host intestinal epithelial cells, and are beneficial to intestinal health. The invention provides a natural and efficient application mode, and has very high conversion value.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The invention discloses traditional Chinese medicine substitutional tea granules for aiding digestion and reducing fat and a preparation method thereof, probiotic microcapsules, traditional Chinese medicine lipid nanoparticles and Tibetan tea active ingredients are combined, and the effects of improving digestion and reducing fat are achieved through a triple synergistic mechanism. The probiotic microcapsules are embedded with citrus fibers through the poria cocos extract and then are mixed with the Chinese yam thick soup for freeze-drying, so that the survival rate of probiotics and the intestinal colonization effect are remarkably improved. The rhizoma alismatis and semen cassiae extracts are encapsulated in lecithin / lauric acid / palmitic acid lipid nanoparticles, so that unpleasant odor is covered, slow release is realized, and the metabolic regulation effects of palmitic acid and lauric acid are coordinated. In addition, Tibetan tea is used as a compound substrate, traditional Chinese medicines such as codonopsis pilosula, hawthorn and poria cocos are fused, honey, coix seeds and Chinese yam are used as auxiliary materials for granulation, and medicinal material natural polysaccharide is used for replacing a chemical adhesive. The product has probiotic activity protection, traditional Chinese medicine slow release and tea fragrance palatability, and has remarkable synergistic advantages in the aspects of improving the digestion function and regulating body fat.

The invention relates to the technical field of dairy products, in particular to a fermented dairy product based on compound ingredient flavor and nutrient enrichment and a preparation method of the fermented dairy product. The raw materials comprise 80-90 parts of raw milk, 3-8 parts of a composite flavor nutrition synergistic ingredient, 2-5 parts of a targeted release type nutrition enhancer, 0.3-1.0 part of a composite probiotic leavening agent, 0.1-0.8 part of a gamma-ray modified functional stabilizer, 0.05-0.2 part of a microencapsulated natural antioxidant, 0.03-0.1 part of an intestinal colonization accelerant and the balance of deionized water. The fermented dairy product disclosed by the invention has the advantages of synergistic flavor and nutrition, high nutrition absorption and utilization rate, strong probiotic colonization capability, good product stability and long shelf life, has both high-quality sensory experience and comprehensive probiotic efficacy, and is superior to the existing fermented dairy product.

The invention discloses screening and application of a drug for inhibiting organ displacement of multi-drug-resistant klebsiella pneumoniae colonized in intestinal tracts. The invention provides any one of the following applications of a substance for inhibiting polarization of macrophages to M2: preparation of a product for treating diseases caused by multi-drug-resistant klebsiella pneumoniae infection; products for treating diseases caused by organ displacement of the multi-drug-resistant klebsiella pneumoniae are prepared; products for treating diseases caused by intestinal colonization of the multi-drug-resistant klebsiella pneumoniae are prepared; preparing a product for inhibiting organ displacement of the multi-drug-resistant klebsiella pneumoniae; preparing a product for inhibiting intestinal colonization of the multi-drug-resistant klebsiella pneumoniae; and a product for reducing or eliminating the number of bacteria in cells or organisms infected with multi-drug-resistant klebsiella pneumoniae is prepared. By inhibiting polarization of macrophages to M2, organ infection and intestinal colonization of multi-drug-resistant klebsiella pneumoniae are effectively inhibited.

The invention belongs to the technical field of prebiotics, and particularly relates to plant extract composite prebiotics as well as a preparation method and application thereof. The invention provides a plant extract composite prebiotics, which is prepared by compounding a purslane ethanol extract and a common turnip ethanol extract in equal mass ratio, and the purslane ethanol extract and the common turnip ethanol extract are prepared by soaking purslane and common turnip in an ethanol solution with the volume concentration of 94-96%, performing ultrasonic extraction, concentrating and freeze-drying. The plant extract composite prebiotics provided by the invention can remarkably promote the growth of probiotics such as lactobacillus plantarum, lactobacillus paracasei and pediococcus pentosaceus, have the effects of regulating intestinal flora balance and promoting intestinal colonization of the probiotics, and also have antioxidant activity, thereby providing a new choice for development of prebiotics with natural sources.